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bendamustine is a cost-effective strategy in the treatment of rituximab-
refractory iNHL.  
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OBJECTIVES: The identification of potential biomarkers in oncology have led to 
the development of companion diagnostics to better select cancer treatment and 
consequently, to increase success rates and potentially reduce costs. The 
objective of this study was to explore the existing evidences regarding the cost-
effectiveness of companion diagnostics in cancer therapy. METHODS: An 
exhaustive literature search previously performed using 4 electronic databases 
from January 1967 until December 2012 allowed retrieving 15,374 studies. Among 
them, 19 studies assessed the economic impact of a companion diagnostic to 
guide therapy or to predict treatment-related toxicity compared with the “no 
testing” strategy. Cost-effectiveness ratios and study parameters were extracted 
from these studies and costs were reported in US$2012. RESULTS: Breast cancer 
was the main indication of the companion diagnostics evaluated. Cost-utility 
analyses (cost per QALY) were performed in 79% of studies. Other studies 
reported results as a cost per case or a cost per life-year gained. Cost of 
companion diagnostic was comprised between $US57 and $US4,469. Cost-
effectiveness ratios of companion diagnostics varied from dominant to 
approximately $US162,000 per QALY. Specifically, using a $50,000 per QALY 
threshold, 9 studies suggested that companion diagnostics are cost-effective or 
could be cost-effective in specific conditions. Furthermore, few companion 
diagnostics were dominated by the “no testing” strategy, depending on the 
method of testing used. In addition, two studies have established a maximum 
cost for the companion diagnostic to be cost-effective. CONCLUSIONS: Most of 
analyzed studies suggest that companion diagnostics are or could be cost-
effective in specific conditions, despite a wide cost-effectiveness ratios range. 
Ratios obtained mainly depend on cancer type, method of testing and cost of 
companion diagnostic.  
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OBJECTIVES: The use of a companion diagnostic to identify subgroups of 
patients most likely to respond to a cancer therapy or to avoid treatment-related 
toxicities can increase success rates of oncology drugs and potentially reduce 
overall treatment costs. The objective of this study was to explore the existing 
evidences regarding economic evaluations of companion diagnostics in cancer 
therapy. METHODS: A structured exhaustive literature search was performed 
using electronic databases from January 1967 until December 2012 to identify 
economic evaluations of companion diagnostics in cancer therapy. Titles were 
initially screened for relevance. Then, abstracts of potentially relevant studies 
were reviewed. Finally, full-text articles were obtained for studies deemed 
relevant according to the abstract and were analyzed in details and relevant 
characteristics were extracted. RESULTS: The literature search allowed retrieving 
15,374 studies. A quick screening of titles allowed excluding 14,014 studies. 
Among the 1,359 abstracts remaining, 235 were economic studies. While the 
large majority of these economic studies evaluated cancer treatment and 
screening cancer methods, 21 were using a companion diagnostic to predict 
treatment response or treatment-related toxicity. Breast cancer was the main 
indication of the companion diagnostics evaluated (57%). Other indications were 
colorectal, leukemia, lung and gastrointestinal tract cancers. Almost all of the 
companion diagnostics evaluated (86%) aimed guiding the choice of the 
treatment and predicting treatment response. A large majority of the economic 
evaluations was model-based studies, with an equal proportion of Markov model 
and decision tree. Cost-utility (cost per QALY) analyses accounted for 57% of 
studies. Approximately 52% adopted a lifetime horizon and 62% used a health 
care system perspective. CONCLUSIONS: Although several companion 
diagnostics have been recently developed, only few of them have been 
economically evaluated in limited cancer types. While choice of methodology 
slightly varies, a relative uniformity in study parameters has been observed 
among economic evaluations.  
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OBJECTIVES: The Centers for Disease Control and Prevention’s Screen for Life: 
National Colorectal Cancer Action Campaign (SFL) is one of the longest-running 
national multimedia campaigns to promote colorectal cancer (CRC) screening for 
men and women aged ≥50 in the United States. Since inception in 1999, no study 
has quantified the benefits and costs of the SFL campaign. METHODS: We 
modeled the impact of the SFL campaign using a range of effect sizes obtained 
from prior studies on the impact of public health mass media campaigns. We 
assumed that the effect size (i.e. the proportion of persons exposed to the 
campaign who are screened as a result of the campaign) would range from 0.5% 
to 10% of unscreened population exposed to the campaign in the last 14 years 
(1999–2012). Using the assumed effect size and other data obtained from the 
literature, we estimated the benefits of the campaign defined as the incremental 
population screened from being exposed to campaign messages. Given the 
estimated benefits of the campaign and costs, we calculated cost per person 
screened (2012 US dollars). RESULTS: If 0.5% of the population exposed to 
campaign messages were screened as a result of the exposure, an additional 
251,000 persons would have been screened from 1999-2012. The average annual 
cost per person screened was $2.44. If the effect size was 10%, an additional 5.01 
million persons would have received screening during this time period as a 
result of the campaign. The average annual cost per person screened was $0.12. 
CONCLUSIONS: The results from this exploratory study indicate that the SFL 
campaign may have contributed to improving CRC screening rates at a minimal 
cost. Our methods provide a model for analyzing the benefits and costs of mass 
media health promotion campaigns when no outcome data are available.  
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OBJECTIVES: Lung cancer remains the leading cause of cancer death in Canada 
and worldwide. Non-small cell lung cancer (NSCLC) accounts for 85% of all lung 
cancers. Conventional treatments of NSCLC have reached the upper bound of 
effectiveness in improving survival and treatment outcomes must still be 
considered disappointing. Recent achievements have been made in the 
understanding of the molecular biology of lung cancer targeted therapies and the 
discovery of new targets, such as the EML4–ALK fusion gene. Targeted therapy 
with ALK inhibitor crizotinib offers significant improvement in clinical outcome 
for treatment of EML4–ALK fusion positive patients. We estimated the cost-
effectiveness of companion EML4-ALK genetic testing in combination with 
crizotinib for NSCLC in Ontario. METHODS: We performed a cost-effectiveness 
analysis using a Markov model from a Ministry of Health perspective and a 
lifetime horizon. Transition probabilities and mortality rates were calculated 
based on the data of 8,113 patients obtained from the Cancer Care Ontario New 
Drug Funding Program database for 2005-2009. Costs were obtained from OCCI 
database, public labs and Princess Margaret Hospital. RESULTS: Our preliminary 
results show that genetic testing and treatment combination strategy gained 0.11 
QALYs when compared to no testing. The incremental cost was CAD $4,320 
compared to standard care, and the incremental cost-effectiveness ratio for the 
base case was $385,438 per QALY. CONCLUSIONS: EML4–ALK genetic testing in 
combination with crizotinib treatment for all NSCLC patients eligible for 
chemotherapy is not economically attractive in the current setting. Lower drug 
costs would be required to make this strategy economically attractive at 
conventional cost effectiveness thresholds  
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OBJECTIVES: Multiple endocrine neoplasia type 2B (MEN2B) is a genetic disease 
that causes multiple tumors on the mouth, eyes, and endocrine glands. The 
prevalence of MEN2B is estimated to be 1 in 600,000 and leads to aggressive, 
usually incurable, medullary thyroid cancer usually during adolescents. MEN2B 
status can be identified by genetic screening and curative thyroidectomy surgery 
offered. Despite the clear benefits MEN2B testing is not part of routine clinical 
management in Australia. The aim of this study is to evaluate the cost-
effectiveness of applying different MEN2B genetic screening strategies in 
Australia. METHODS: A decision analytical model was constructed to evaluate 
cost per quality-adjusted life-year, life-years gained and case detected by 
comparing three competing strategies: 1) no MEN2B testing, 2) screening every 
newborn baby and 3) screening only patients that attend Marfan’s clinics (it is 
estimated that 85% of the MEN2B carriers express Marfanoid habitus, and 
consequently will be tested for Marfan syndrome). The impact of uncertainty 
was evaluated using probabilistic sensitivity analysis. RESULTS: Current practice 
(No MEN2B testing) is dominated by providing MEN2B testing at Marfan’s clinics; 
this is because the cost of screening is more than offset by the cost of cancer 
treatment avoided. When comparing newborn screening (population based 
screening) to providing MEN2B testing at Marfan’s clinics, the incremental cost-
effectiveness ratio (ICER) is $8,669 per QALY gained. The cost per case detected is 
$36,235 when providing gene testing at Marfan’s clinics and $407,200 in the 
newborn screening strategy. Prevalence of MEN2B and the cost of MEN2B testing 
in Newborn screening are important parameters. CONCLUSIONS: Genetic 
screening on an individual’s risk of cancer is an appealing prospect. We 
demonstrated that performing MEN2B testing at Marfan’s clinics is likely to be 
cost-saving, compared to current practice. Whilst screening all newborn babies 
may also be a cost-effective option.  
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OBJECTIVES: To compare the cost-effectiveness of various cervical cancer (CxCa) 
screening algorithms to primary screening with the cobas HPV Test, which 
identifies HPV genotypes 16/18 individually while simultaneously detecting the 
other high-risk HPV types. METHODS: A cohort Markov model was developed to 
compare four CxCa screening strategies: (S1) cytology with reflex HPV, (S2) 
cytology and HPV co-testing, (S3) HPV with reflex cytology, and (S4) cobas HPV 
with genotyping and reflex cytology. Screening began at age 30 with a routine 
screening interval of every 3 years, and was modeled over a time horizon of 40 
years. Performance of the overall screening strategies, ie, sensitivity and 
specificity for CIN 2/3, was derived from the ATHENA (Addressing THE Need for 
Advanced HPV Diagnostics) trial. Trial baseline data were used for the base case, 
and 1-year follow-up outcomes were estimated for the alternative scenario, 
assuming all persistent disease is detected in the subsequent visit. The direct 
costs for screening and treatment of CxCa were estimated from a US payer 
perspective in 2010 US dollars. Costs and quality-adjusted life years (QALYs) 
were discounted at 3% annually. One-way sensitivity analyses were conducted. 
RESULTS: Using a $50,000/QALY threshold, baseline screening with S4 
dominated S2 and S3 by reducing overall cost, annual cancer incidence, and 
improving QALYs; and was cost-effective compared to S1. In the 1-year follow-up 
scenario, S4 was cost-effective compared to all other strategies. Detection of HPV 
16/18 with S4 resulted in earlier diagnosis of clinically relevant CIN 2/3 at the 
initial visit as well as more efficient use of screening tests during follow-up. 
Sensitivity analyses showed that the model results were most influenced by the 
costs of tests used. CONCLUSIONS: Incorporating the cobas HPV test with HPV 
16/18 genotyping was cost-effective compared to various CxCa screening 
strategies, and resulted in improved protection against CxCa.  
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OBJECTIVES: To compare the costs and outcomes of enzalutamide versus 
abiraterone for the treatment of docetaxel refractory metastatic castrate 
resistant prostate cancer (mCRPC) from a limited societal perspective using a 
lifetime horizon. METHODS: We developed a Markov model with 3 health states: 
pre-progression, post-progression, and death with 1 month transitions. 
Transition probabilities for all health states were derived from the pivotal phase 
3 clinical trials: AFFIRM (enzalutamide) and COU-AA-301 (abiraterone). A 3% 
discount was applied to all costs and outcomes. Costs included drug acquisition 
costs, laboratory tests associated with treatment, as well as costs for grade 3/4 
side effects management. Outcomes were assessed in quality-adjusted life-years 
(QALYs). We conducted 16 univariate sensitivity analyses varying model inputs 
(overall survival, progression-free survival, utility, drug acquisition cost) for each 
respective drug independently by 20%. RESULTS: In the base case analysis, we 
found that the costs for enzalutamide were higher than that of abiraterone, 
primarily due to higher acquisition costs ($84465, $74119 respectively). 
Enzalutamide was also associated with greater life years gained than abiraterone 
(1.39, 1.30 respectively) as well as QALYs gained (1.24, 1.05 respectively). The ICER 
was $55070/QALY. Sensitivity analyses indicated that the ICER varied widely; 
using commonly accepted thresholds of $50000/QALY and $100000/QALY, we 
found that out of the 16 sensitivity analyses conducted, 4 fell below the 
$50000/QALY threshold and 7 fell below the $100000/QALY threshold. 
CONCLUSIONS: The treatment landscape of mCRPC has shifted dramatically in 
recent years. Where there previously had been few options for patients, the last 
2 years have brought multiple new therapies for mCRPC. To our knowledge, this 
is the first study which compares the cost-effectiveness of enzalutamide to 
abiraterone. Our results suggest that there is considerable uncertainty regarding 
the cost-effectiveness of enzalutamide, but enzalutamide will likely play a 
significant role in the treatment of mCRPC.  
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OBJECTIVES: In South Africa, females with over expressed human epidermal 
growth factor receptor 2 (HER2) positive metastatic breast cancer are often 
treated with trastuzumab. Lapatinib is an oral dual tyrosine kinase inhibitor and 
is indicated, in combination with capecitabine, for the treatment of patients with 
advanced or metastatic breast cancer. We estimate the cost-effectiveness of the 
use of lapatinib in the private health care sector from a payer perspective. 
METHODS: A cost-utility model was modified for appropriate application in the 
South African private health care sector setting. We compared treatment with 
capcitabine mono-therapy with several trastuzumab combination therapies as 
well as lapatinib in combination with capcitabine. Efficacy data was taken from 
the EGF100151 trial. The efficacy of trastuzumab containing regiment was 
assumed to be the same as that of a lapatanib containing regiment due to a lack 
of data. Sixteen key opinion leader oncologists were consulted through a 
structured questionnaire. Resource consumption costs were estimated from 
large private medical scheme claims data. A multistate model was used and run 
for the full lifetime of a patient. RESULTS: Lapatinib in combination with 
capecitabine dominates the combination of other treatment options investigated 
in this study. The incremental cost in this comparison equates to -US$3,619 with 
a gain of 0.032 quality adjusted life-years. The results were robust under 
sensitivity analyses. CONCLUSIONS: The use of lapatinib dominates other 
treatments. The majority (84%) of patients in the comparator arm use 
trastuzumab, and based on the fact that the AE costs are relatively low, the 
results are mainly driven by the difference in the cost of trastuzumab and 
lapatinib. The validity of the assumption of equal efficacy of trastuzumab and 
lapatinib is therefore key when interpreting the results and needs to be verified 
with additional data.  
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OBJECTIVES: To explore the chronic myeloid leukemia (CML)-related health  
care costs, utilizations associated with nonadherence and interruption of 
tyrosine kinase inhibitors (TKIs) in newly diagnosed CML patients. METHODS: 
This retrospective cohort study was conducted from 2003 to 2011 using the 
Taiwan Health Insurance Research Database. Newly diagnosed CML patients 
who received TKIs (imatinib, dasatinib and nilotinib) for more than one year 
during 2003 to 2010 were included in this study, and followed from the first TKI 
prescription date to death or end of study. CML-related medical utilization 
(number of outpatient and inpatient visits) and costs were calculated  
and stratified by TKI utilization pattern comparing interruption versus 
persistence and non-adherence versus adherence. Any gap between  
two consecutive prescriptions for more than 60 days and medicine possess ratio 
less than 80% were defined as interruption and non-adherence. Data were 
analyzed by generalized linear models with log link and gamma distributions. 
RESULTS: Of the 991 included patients, 24.6% and 15.8% were identified  
as interruption and non-adherence groups. Non-adherence and interruption 
rates were higher in patients who received increasing dose of imatinib, imatinib 
switched to dasatinib and imatinib switched to nilotinib. Adjusted outpatient 
cost per person year was higher in persistence (US$31,443±1,456)  
than interruption (US$22,071±1,163) group (p<0.0001); and higher in adherence 
(US$30,295±1,230) than non-adherence (US$18,259±1,050) group (p<0.0001). 
However, adjusted inpatient cost per person year was higher in interruption 
(US$5,674±1,665 vs. US$2,442±613; p<0.0001) and non-adhernece (US$6,390±1,866 
vs. US$2,260±557; p<0.0001) groups. Likewise, CML-related inpatient visits  
per person year was higher in interruption (1.3 vs. 0.9; p=0.0093) and non-
adherence (1.4 vs. 0.9; p=0.0251). CONCLUSIONS: Interruption and non-
adherence to TKIs are associated with higher inpatient utilization and costs. 
Further study need to evaluate the clinical consequence and costs related to TKIs 
interruption and nonadherence for maximizing the efficiency of medical 
utilizations.  
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OBJECTIVES: Even though prostate cancer has one of the highest incidences of 
cancer, there is very limited data available on treatment patterns in Brazil. This 
study aimed to describe treatment patterns and health care resource utilization 
associated with PC in Brazil in 2012. METHODS: Overall clinical practice for 
management of prostate cancer was investigated through a physician face-to-
face survey. Eligible criteria were medical oncologists and/or urologists with 
clinical experience with prostate cancer patients, including hormonal therapy, 
with a minimum volume of 30 patients/month. Clinical experts were 
consecutively selected based on a high prescriber database and stratified by type 
of health care sector (public/private). RESULTS: Twenty physicians (70% 
oncologists; 30% urologists) currently treating 1,325 patients answered the 
questionnaire. Significant differences were found on treatment patterns when 
comparing public and private health care physician responses. In localized PC 
patients, radical prostatectomy was more commonly used in the private than in 
the public settings. For advanced stage patients, surgical androgen deprivation 
therapy (ADT) was used in 7% in private health care and in 37% of public 
patients. In metastatic castration resistant patients (mCRPC), first line 
chemotherapy of choice was docetaxel. However, second line treatment varied 
between mitoxantrone (32% private, 50% public), cabazitaxel (54% private, 18% 
public) and docetaxel re-challenge (11% private, 29% public). Health care resource 
utilization increases as disease progresses: from mean 14.1 blood tests/year 
(blood count, blood chemistry, functional liver test and PSA) in localized PC while 
receiving treatment to 22 blood tests/year in advanced tumor and 40.05 blood 
tests/year in mCRPC. The same trend is observed with specialist visits and 
emergency room, but not with image testing. CONCLUSIONS: Both treatment 
patterns and resource use are different when comparing private and public 
settings. Access to new technologies may be an important factor in explaining 
this difference.  
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